Pediatric-plan strategist must resolve whether the primary endpoint will

Situation

FDA Response and Labeling work in an RWE group proposing a post-marketing study instead of a new RCT now turns on the primary endpoint will because a site-change that invalidates stability claims put biosimilar analytical similarity report in play. Pediatric-plan strategist should say what biosimilar analytical similarity report proves.

Decision

Pediatric-plan strategist in an RWE group proposing a post-marketing study instead of a new RCT must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using biosimilar analytical similarity report after a site-change that invalidates stability claims.

Hypotheses to test

• Authorize Proceed under protocol now; biosimilar analytical similarity report already has the discriminator after a site-change that invalidates stability claims.
• Keep Pause the pathway in force until biosimilar analytical similarity report is completed after a site-change that invalidates stability claims for pediatric-plan strategist.
• Treat biosimilar analytical similarity report as Escalate safety review because both readings appear after a site-change that invalidates stability claims.
• Refuse a Pharma & Life Sciences close: pediatric-plan strategist does not have the page the primary endpoint will turns on in biosimilar analytical similarity report.

Analysis required

• Check whether biosimilar analytical similarity report supports the labeled claim pediatric-plan strategist would keep.
• Map FDA-response timing and owner in an RWE group proposing a post-marketing study instead of a new RCT.
• Trace CMC, labeling, or pharmacovigilance facts in biosimilar analytical similarity report after a site-change that invalidates stability claims.
• For this Pharma & Life Sciences FDA Response and Labeling file, read biosimilar analytical similarity report against a site-change that invalidates stability claims and write the one fact that would move the primary endpoint will for pediatric-plan strategist.

Recommendation

Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / FDA Response and Labeling packet (biosimilar analytical similarity report after a site-change that invalidates stability claims). The follow-on FDA Response and Labeling action is what pediatric-plan strategist does next: implement the option, assign an owner, and log the missing fact.